Cellosaurus logo
expasy logo

Cellosaurus YUSIT1-B11 (CVCL_R736)

[Text version]
Cell line name YUSIT1-B11
Accession CVCL_R736
Resource Identification Initiative To cite this cell line use: YUSIT1-B11 (RRID:CVCL_R736)
Comments Selected for resistance to: ChEBI; CHEBI_75045; Dabrafenib (Tafinlar; GSK2118436).
Derived from site: Metastatic; Not specified.
Sequence variations
  • Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (from parent cell line).
Disease Melanoma (NCIt: C3224)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_A747 (YUSIT1)
Sex of cell Male
Age at sampling 67Y
Category Cancer cell line
Publications

PubMed=22389471; DOI=10.1158/1535-7163.MCT-11-0989
Greger J.G., Eastman S.D., Zhang V., Bleam M.R., Hughes A.M., Smitheman K.N., Dickerson S.H., Laquerre S.G., Liu L., Gilmer T.M.
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Mol. Cancer Ther. 11:909-920(2012)

Patent=US20130231347
Bleam M.R., Gilmer T.M., Greger J.G., Laquerre S.G., Liu L.
Method of treatment with BRAF inhibitor.
Patent number US20130231347, 05-Sep-2013

Cross-references
Cell line databases/resources cancercelllines; CVCL_R736
Encyclopedic resources Wikidata; Q54995803
Polymorphism and mutation databases Cosmic; 1921231
Entry history
Entry creation05-Nov-2013
Last entry update19-Dec-2024
Version number15